| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,350 |
9,177 |
$614K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,565 |
7,495 |
$331K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,838 |
5,016 |
$201K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,970 |
2,728 |
$162K |
| 87428 |
|
2,231 |
1,710 |
$98K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,254 |
2,716 |
$85K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,116 |
880 |
$47K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,813 |
5,125 |
$46K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,097 |
1,768 |
$30K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,492 |
1,112 |
$23K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,115 |
879 |
$14K |
| 99215 |
Prolong outpt/office vis |
90 |
87 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
382 |
335 |
$6K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
370 |
291 |
$4K |
| 81025 |
|
818 |
737 |
$4K |
| 81003 |
|
2,045 |
1,844 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
189 |
156 |
$2K |
| 87807 |
|
185 |
146 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
232 |
198 |
$818.63 |
| 0011A |
|
24 |
22 |
$800.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
98 |
86 |
$596.27 |
| 90686 |
|
84 |
67 |
$576.72 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
31 |
25 |
$332.02 |
| 87081 |
|
60 |
49 |
$261.56 |
| 90674 |
|
12 |
12 |
$176.85 |
| 73610 |
|
12 |
12 |
$165.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
182 |
158 |
$127.80 |
| 80053 |
Comprehensive metabolic panel |
15 |
12 |
$127.12 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
24 |
19 |
$111.93 |
| H0033 |
Oral medication administration, direct observation |
218 |
211 |
$100.80 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
377 |
331 |
$50.92 |
| 99000 |
|
124 |
97 |
$18.54 |
| A9150 |
Non-prescription drugs |
178 |
163 |
$18.49 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
52 |
49 |
$7.82 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
13 |
12 |
$2.66 |
| 90749 |
|
18 |
13 |
$0.00 |
| 91301 |
|
40 |
37 |
$0.00 |